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Purpose. To develop a prognostic model for predicting survival after palliative reirradiation (PR). Methods and Materials. We
analyzed all 87 PR courses administered at a dedicated palliative radiotherapy facility between 20.06.2007 (opening) and 31.12.2009.
Uni- and multivariate survival analyses were performed, the previously published survival prediction score (SPS) was evaluated,
and a PR-specific prognostic scorewas calculated.Results. Inmultivariate analysis, four parameters significantly influenced survival:
performance status, use of steroids, presence of liver metastases, and pleural effusion. Based on these parameters, a 4-tiered score
was developed. Median survival was 24.5 months for the favorable group, 9.7 and 2.8 months for the two intermediate groups, and
1.1 months for the unfavorable group (𝑃 = 0.019 for comparison between the two favorable groups and 𝑃 ≤ 0.002 for all other pair-
wise comparisons). All patients in the unfavorable group died within 2 months. Conclusion. The performance of PR-specific score
was promising and might facilitate identification of patients who survive long enough to benefit from PR. It should be validated in
independent patient groups, ideally from several institutions and countries.
1. Introduction
Palliative reirradiation is currently used in a variety of clinical
settings, including but not limited to bone and brain metas-
tases or lung and gynecological cancers [1–4].The number of
scientific publications on this topic has increased in recent
years [5]. In a well-defined geographical part of Norway,
palliative reirradiation contributed 10% to all palliative radio-
therapy series administered during a 12-month period [6].
Randomized trials comparing single versusmultiple fractions
for painful bone metastases reported retreatment rates of 11–
42% after a single fraction and 0–24% aftermultiple fractions,
as summarized by Chow et al. [1]. Comparable to palliative
radiotherapy in general, clinicians attempt to tailor treat-
ment regimens to patients’ prognosis, thereby minimizing
undesirable over- and undertreatment. Decision aids such as
prognostic scores and nomograms might facilitate rapid and
reproducible assessment of patients’ survival expectation by
transforming the complex set of patient- and disease-related
prognostic factors into a standardized tool. Ideally, prognos-
tic scores are easy to administer and valid across different
institutions and countries [7]. The Survival Prediction Score
(SPS), developed and validated by Chow et al. in patient
cohorts treated with palliative radiotherapy, is among the
tools that might be widely applicable, because it is based on
three readily available parameters: primary cancer type, site
of metastases, and performance status [8]. Its performance
has never been tested specifically in patients undergoing
palliative reirradiation. Together with a large number of other
baseline factors potentially impacting survival, we analyzed
SPS in a single-institution cohort study.
2. Methods
We retrospectively reviewed the records of all consecutive
patients who received palliative reirradiation at a single
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hospital with dedicated palliative radiotherapy unit. The
patients started their treatment in the time period from
June 20, 2007 (date of opening of the dedicated palliative
radiotherapy unit), to December 31, 2009. Reirradiation was
defined as partial or complete field overlap (examples of par-
tial overlap: initial course included thoracic vertebrae Th4-
6 and reirradiation Th6-8; initial course of radical prostate
radiotherapy followed by pelvic bone metastasis irradiation).
A total of 87 reirradiation courses were studied. Stereotactic
radiotherapy was unavailable and thus not included in the
present series. All medical records, treatment details, and
information on date of death were available in the hospital’s
electronic patient record (EPR) system. The survival status
and date of death or last follow-up of the patients were
obtained from the EPR. Patients who were lost to follow-
up were censored on the date of last documented contact
(personal appointment, telephone conversation, and blood
test). Median follow-up for all surviving/censored patients
was 5.4 months. Survival time was measured from the start
of reirradiation. Actuarial survival curves were generated
by Kaplan-Meier method and compared by log-rank test
(analyses performed with IBM SPSS Statistics 20). Multivari-
ate analyses were performed by Cox regression (backward
conditional method). We assigned SPS as described by Chow
et al. [8], that is, based on three variables (nonbreast cancer,
metastases other than bone, and Karnofsky performance
status (KPS) ≤ 60): poor prognosis group when all three
were present, intermediate prognosis group when two were
present, and good prognosis group when 0-1 were present.
Our own prognostic scores were developed as previously
described by Rades et al. [9, 10]. In brief, the score for each
predictive factor was determined by dividing the actuarial
death rate at prespecified time points (given as the per-
centage) by 10. For example, patients with good KPS were
assigned 0 points and those with poor KPS 1.5 points (rate
of death at 1 month (15%) divided by 10). The total score
represented the sum of the scores for each predictive factor.
Two time points reflecting poor prognosis or short survival
were chosen, 1 month and 2 months, because there is no
generally agreed definition of sufficient survival expectation,
justifying initiation of palliative radiotherapy. Given that
recent research anddiscussions focused on overtreatment, for
example, use of radiation therapy in the last 30 days of life, we
felt that predicting short survival might be more important
[11–14].
3. Results
Median age at the time of reirradiation was 67 years (range
38–90 years). Prostate (29%) and non-small cell lung cancer
(NSCLC, 11%) were the most common primary tumors.
Additional baseline information is shown in Table 1. Bone
metastases were the prevailing target for reirradiation. The
most common regime consisted of 10 fractions of 3Gy
(43%). Other common regimes included 8Gy single fraction
(uncomplicated bone metastases) and 5 fractions of 4Gy
(various sites and indications). Five courses (6%) remained
incomplete, typically because of earlier than expected clinical
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Figure 1: Actuarial overall survival after palliative reirradiation
(Kaplan-Meier estimate).
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Figure 2: Actuarial overall survival after palliative reirradiation
stratified by SPS score (Kaplan-Meier estimate): group 1 (𝑛 = 23),
median not reached; group 2 (𝑛 = 26), median 6.7 months; group
3 (𝑛 = 38), median 4.1 months; 𝑃 = 0.26 for group 2 versus 3 and
𝑃 < 0.05 for other comparisons.
deterioration. Median survival of this small group of patients
was 2.8 months. Overall median survival from reirradiation
was 8.6 months and 1-year survival rate 42% (Figure 1). Six
percent of patients received radiotherapy during the final
month of life. Seventeen percent of patients died within 2
months.
We analyzed the potential prognostic impact of all base-
line parameters shown in Table 1 and assigned SPS score.
However, the performance of this score was unsatisfactory
because two of the three patient groups had similar survival
(Figure 2). As shown in Table 2, two components of the
SPS score (metastases location and performance status)
significantly influenced survival, while primary tumor type
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Table 1: Patient characteristics.
Characteristic No. %
Entire cohort 87
Gender
Male 65 75
Female 22 25
Family status1
Single 20 23
Married 55 63
Partner 5 6
Missing information 7 8
Karnofsky performance status
90–100 31 36
70–80 30 34
≤60 26 30
Primary tumor site
Prostate 25 29
Breast 9 10
Lung (non-small cell) 10 11
Colorectal 8 9
Bladder 5 6
Kidney 6 7
Skin (malignant melanoma) 3 3
Other 21 24
Dose/fractionation (intention-to-treat)
10 fractions of 3Gy 24 28
Single fraction of 8Gy 19 22
5 fractions of 4Gy 15 17
12–15 fractions of 2.5 Gy 4 5
Other 25 29
Reirradiation target types
Bone metastases 69 79
Brain metastases 5 6
Lung metastases or primary tumor 6 7
Other 7 8
Known brain metastases
No 80 92
One or more 7 8
Known liver metastases
No 68 78
One or more 19 22
Known lung metastases
No 65 75
One or more 22 25
Known adrenal gland metastases
No 76 87
One or more 11 13
Known bone metastases
No 14 16
One or more 73 84
Metastatic spinal cord compression
No 80 92
Yes (radiologic or symptomatic) 7 8
Pleural effusion
No 81 93
Yes (radiologic or symptomatic) 6 7
Table 1: Continued.
Characteristic No. %
Number of metastatic sites
0 10 11
1 (e.g., lungs only) 37 43
2 (e.g., lungs and brain) 27 31
3 11 13
4 2 2
Progressive disease outside RT target volume1
No 27 31
Yes 55 63
Missing information 5 6
Systemic cancer treatment1
No 23 26
Within 4 weeks before RT 21 24
Within 3 months before RT 14 16
Earlier 17 20
Missing information 12 14
Use of opioid analgetics at start of RT1
No 21 24
Yes 54 62
Missing information 12 14
Use of steroids at start of RT1
No 32 37
Yes 38 44
Missing information 17 20
Serum hemoglobin1
Low2 66 76
Normal 16 18
Missing information 5 6
Serum albumin1
Low2 17 20
Normal 42 48
Missing information 28 32
Serum lactate dehydrogenase1
Normal2 14 16
Elevated 35 40
Missing information 38 44
Serum alkaline phosphatase1
Normal2 25 29
Elevated 29 33
Missing information 33 38
Serum creatinine1
Low2 13 15
Normal 48 55
Elevated 15 17
Missing information 11 13
Serum C-reactive protein1
Normal2 20 23
Elevated but less than 30mg/L 27 31
Elevated 30–60mg/L 14 16
Elevated >60mg/L 17 20
Missing information 9 10
Thrombocyte count1
Low2 11 13
Normal 45 52
High 19 22
Missing information 12 14
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Table 1: Continued.
Characteristic No. %
Charlson comorbidity index1
0 7 8
1-2 44 51
3 or more 28 32
Missing information 8 9
Smoking status1
Current smoker 34 39
No 34 39
Missing information 19 22
RT: radiotherapy.
1Missing information in some cases.
2Hematology and blood chemistry results refer to institutional limits of nor-
mal; only test results obtained within one week before RT were considered.
did not. In multivariate analysis, a total of four parame-
ters significantly influenced survival: KPS, use of steroids,
presence of liver metastases, and pleural effusion. Based
on these parameters, a new 4-tiered prognostic score was
developed. As described in Section 2, we compared two
different variants, which are shown in Table 3. When apply-
ing a short-survival-definition of 1 month (variant 1), the
resulting survival curves separated clearly (Figure 3). Median
survival was 24.5 months for the favorable group, 9.7 and
2.8 months for the intermediate groups, and 1.1 months for
the unfavorable group (𝑃 = 0.024 for comparison between
the two favorable groups and 𝑃 ≤ 0.003 for all other
pair-wise comparisons). Thirty-three percent of patients in
the unfavorable group died within 1 month and all within
2 months. When applying a short-survival-definition of 2
months (variant 2), the resulting survival curves separated
equally clear (Figure 4).Median survival was exactly the same
as in variant 1 (𝑃 = 0.019 for comparison between the
two favorable groups and 𝑃 ≤ 0.002 for all other pair-wise
comparisons). Since the unfavorable group included exactly
the same patients, 33% died within 1 month and all within 2
months. Because of its superior significance level, variant 2
might be the preferred assignment method.
4. Discussion
Palliative reirradiation is an important treatment option,
providing symptom improvement inmany patientswith bone
metastases [1] and other conditions [15].Whilemost previous
studies were small and often retrospective, the randomized
bone metastases study by Chow et al. comparing different
fractionation regimens included 850 patients [1]. Median
survival in the two arms was 9.3 and 9.7 months, respectively.
This result is comparable to the 8.6 months reported in our
own, bonemetastases-dominated study. However, survival of
individual patients might be as short as few days or as long as
several years (Figure 1).Therefore, prognostic scoresmight be
valuable decision aids when prescribing palliative reirradia-
tion. Chow et al. have previously published several reports on
a score for patients receiving palliative radiotherapy in gen-
eral, the SPS. Development of this predictionmodel started in
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Figure 3: Actuarial overall survival after palliative reirradiation
stratified by new score, variant 1 (Kaplan-Meier estimate): median
24.5 (0 points) versus 9.7 (1–1.5 points) versus 2.8 (2-3 points) versus
1.1 months (>3 points), 𝑃 = 0.024 for comparison between group
1 and 2, 𝑃 ≤ 0.003 for all other pair-wise comparisons. Number
of patients in each group: 20, 24, 20, and 6. Missing information to
assign score in 17 patients.
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Figure 4: Actuarial overall survival after palliative reirradiation
stratified by new score, variant 2 (Kaplan-Meier estimate): median
24.5 (4-5 points) versus 9.7 (6–8 points) versus 2.8 (9–11 points)
versus 1.1 months (>11 points), 𝑃 = 0.019 for comparison between
group 1 and 2, 𝑃 ≤ 0.002 for all other pair-wise comparisons.
Number of patients in each group: 20, 26, 18, and 6. Missing
information to assign score in 17 patients.
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Table 2: Prognostic factors for survival. All baseline variables shown in Table 1 were analyzed (univariate, log-rank test). Those with 𝑃 value
<0.1 were carried forward to multivariate Cox regression analysis and are shown here.
Characteristic Median survival (months) 𝑃 value
Univariate1 Multivariate
Karnofsky PS
90–100 18.3
0.0001 0.000170–80 9.4
≤60 2.1
Known brain metastases
No 9.7 0.008 n.s.
Yes 3.6
Known liver metastases
No 9.7 0.037 0.039
Yes 2.8
Pleural effusion
No 9.4 0.007 0.039
Yes 1.3
Number of metastatic sites
Max. 2 9.7 0.054 n.s.
3 or more 2.8
Progressive disease outside RT target volume
No 12.6 0.033 n.s.
Yes 5.5
Use of opioid analgetics
No 24.5 0.02 n.s.
Yes 5.2
Use of steroids
No 12.2 0.002 0.015
Yes 3.6
Serum albumin
Low 9.7 0.001 n.s.
Normal 2.8
Serum alkaline phosphatase
Normal 15.1 0.027 n.s.
Elevated 4.1
Serum creatinine
Low 1.6
0.0001 n.s.Normal 9.7
Elevated 15.1
Serum C-reactive protein
Normal 18.3
0.0001 n.s.Elevated but less than 30mg/L 12.6
Elevated 30–60mg/L 5.3
Elevated >60mg/L 2.6
Thrombocyte count
Low 12.7
0.038 n.s.Normal 9.7
High 4.0
Number of abnormal blood tests2
Max. 1 12.7
2 5.8 0.008 n.s.
3 or more 3.0
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Table 2: Continued.
Characteristic Median survival (months) 𝑃 value
Univariate1 Multivariate
Smoking status
Current smoker 4.3 0.063 n.s.
No 9.7
Time from first cancer diagnosis
Shorter than median (47 months) 5.3 0.089 n.s.
Longer than median 9.7
RT: radiotherapy; PS: performance status.
1If more than 2 groups, 𝑃 value from log-rank test pooled over all strata.
2All tests shown in Table 1 were considered.
Significance levels were not corrected for multiple tests.
Table 3: Prognostic scores based on four parameters predicting survival in multivariate analysis. Endpoints: death within 1 month (variant
1) and death within 2 months (variant 2).
Parameter Died within 1 month Points1 Died within 2 months Points1
Karnofsky PS
70–100 2% 0 7% 1
≤60 15% 1.5 39% 4
Known liver metastases
No 4% 0 8% 1
Yes 11% 1 49% 5
Pleural effusion
No 4% 0 14% 1
Yes 33% 3 50% 5
Use of steroids
No 3% 0 10% 1
Yes 11% 1 28% 3
Minimum sum score 0 4
Maximum sum score 6.5 17
PS: performance status.
1Death rate divided by 10.
395 patients referred to their palliative radiotherapy program
[16]. Later, they refined their original six-parameter-model by
reducing the number of variables to three (primary cancer
type, site of metastases, and performance status), arriving at
the SPS [8, 17]. We hypothesized that this score might also
predict survival of patients receiving reirradiation but discov-
ered that further studies, which also include other models,
are needed. The performance of the SPS score (Figure 2)
can be explained by the fact that not all adverse SPS features
(nonbreast cancer, metastases other than bone, and poor
performance status) influenced prognosis of reirradiated
patients. In the present study, metastases location and perfor-
mance status significantly influenced survival, while primary
tumor type did not.
Disadvantages of our study include its retrospective
design and limited number of patients, especially regarding
subgroups. Not all patients had complete information on
all baseline parameters recorded in the EPR system. The
majority of reirradiation courses consisted of hypofraction-
ated regimens, mostly 1–15 fractions, with dose/fractionation
parameters reflecting a patient’s expected prognosis (clinical
estimate). We did not use any particular prognostic models
or scores when assigning treatment regime during the time
period covered in our study. Nevertheless, more than 90% of
patients who were offered reirradiation also completed their
treatment. Only 6% were treated during the final month of
life, suggesting that our clinical decision making was largely
successful, even if further improvement should be attempted.
Our score based on KPS, use of steroids, presence of liver
metastases, and pleural effusion performed promisingly. To
the best of our knowledge, no other scores related specifically
to palliative reirradiation exist. One of the clinical aims of
applying prognostic scores might be avoidance of overtreat-
ment in patients with very short survival [18]. Recently,
Tanvetyanon et al. have reported on use of radiotherapy in the
last 30 days of life in the United States [19].They used a SEER-
Medicare linked database to obtain a large study cohort of
202,299 patients who died as a result of lung, breast, prostate,
colorectal, and pancreas cancers (top five cancer causes of
death) between January 1, 2000, and December 31, 2007. The
rate of radiotherapy in the last 30 days of life, by many
regarded as inappropriate overtreatment, though this point
of view is controversial, was 7.6%. No data on reirradiation
were reported in this study, and no attempt was made to
develop predictive models. Before our new score can be
widely implemented, external validation is necessary. In the
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future, it might become possible to study narrowly defined
patient groups, if sufficiently large databases can be created.
For example, Tanvetyanon et al. have published prognostic
factors for survival after salvage reirradiation in patients with
head and neck cancer [19]. Rades et al. have developed scores
specific to metastatic spinal cord compression [20, 21], and
Sperduto et al. to brain metastases [22], both related to first
line treatment rather than reirradiation.
5. Conclusions
Prognostic factors for survival might change during the
course of disease, for example, from first line to subsequent
treatments. The performance of the newly developed score
was promising and might facilitate identification of patients
who survive long enough to benefit from palliative reirradi-
ation. It should be validated in independent patient groups,
ideally from several institutions and countries.
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